Legend’s Carvykti (ciltacabtagene autoleucel) Receives the EC’s Approval for the Treatment of Relapsed and Refractory Multiple Myeloma
Shots:
- The conditional approval was based on the P-Ib/II (CARTITUDE-1) study evaluating Carvykti in patients (n=97) with r/r multiple myeloma who have received 3 prior lines of treatment incl. PI, IMiD & anti-CD38 mAb
- The results showed a median duration of 18mos. follow up, deep & durable responses on one-time treatment, patients with CI (98%) & sCR (80%). The safety profile of Carvykti was evaluated on patients (n=179) in the (MMY2001) & (MMY2003) trials
- Carvykti is a BCMA-directed genetically modified autologous T-cell immunotherapy that can reprogramme a patient’s T-cells with a transgene encoding CAR which identifies & eliminates BCMA-expressing cells. Additionally, Carvykti was approved by the US FDA on Feb’22
Ref: Businesswire | Image: Legend
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
